Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with T1DM.~* Participants on continuous insulin treatment for at least 12 months prior to screening.~* Participants exclusively on a multiple (greater than or equal to 3) daily injection insulin analogue regimen using:~  * NovoLog as mealtime insulin for at least 12 weeks prior to screening and~ * Insulin glargine (100 units per milliliter \[U/mL\]) as basal insulin for at least 12 weeks prior to screening. Note: Participants not meeting this criterion could also qualify, provided that they completed the run-in period during which NovoLog and Lantus was administered so that, at the time of randomization, the participants had been on NovoLog and insulin glargine (100 U/mL) for at least 12 weeks (including any potential pre-screening administration).~* Glycated hemoglobin (HbA1c) less than or equal to 10 percent (%) (85.79 millimoles per mole) at screening.~* Body mass index less than or equal to 35 kilograms per meter square (kg/m\^2) at screening.~Exclusion criteria:~* Pancreatectomy and/or islet cell transplantation.~* Clinically significant laboratory findings, as defined by the protocol.~* Known presence of factors that interfered with the HbA1c measurement.~* History of severe hypoglycemia required emergency room admission or hospitalization within 3 months prior to screening.~* Hospitalization for recurrent diabetic ketoacidosis within 3 months prior to screening.~* Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.~* Use of glucose lowering treatments other than the multiple dose injections and basal insulin regimen (including use of insulin pump therapy), within 12 weeks prior to screening.~* Participants had received systemic glucocorticoids for one week or more within 3 months prior to screening (topical, nasal spray, inhaled or intra-articular applications are allowed).~* Participants had received systemic immunosuppressive agents within 6 months prior to screening.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switching: NovoLog/SAR341402 (Type: EXPERIMENTAL): Participants self-administered subcutaneous (SC) injection daily prior to the start of a meal during the 16-week treatment period, starting with NovoLog (100 units per milliliters \[U/mL\]) for the first 4 weeks, then SAR341402 (100 U/mL) for 4 weeks, followed by NovoLog (at same dose) for 4 weeks and then SAR341402 (at same dose) for the last 4 weeks on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.
- Non-Switching: NovoLog (Type: ACTIVE_COMPARATOR): Participants self-administered SC injection of NovoLog (100 U/mL) daily prior to the start of a meal during the 16-week treatment period on top of mandatory background therapy with Lantus (Insulin glargine, 100 U/mL) as basal insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).